Why the study?
Does serum NT-proBNP identify left ventricular hypertrophy in hypertensive patients better than CK-MB and myoglobin?
Does serum NT-proBNP identify left ventricular hypertrophy in hypertensive patients better than CK-MB and myoglobin?
Serum NT-proBNP is a useful biomarker for identifying left ventricular hypertrophy in hypertensive patients, outperforming traditional markers like CK-MB and myoglobin.
Supports NT-proBNP as a potential screening tool for hypertensive heart disease; leaves open whether.
Objective: Left ventricular hypertrophy (LVH) is an independent risk factor for all cardiovascular complication of Hypertension, in this group early detection is very important for better management. Therefore, the aim of our study is to evaluate cardiac markers in hypertension with LVH.Material and Methods: The study comprised of 95 patients with the evidence of Hypertension. These cases were further divided into 2 groups i.e. Hypertension without LVH and Hypertension with LVH groups. We assessed blood pressure, electrocardiography and echocardiography. All the cardiac markers are assessed by using ELISA.Results: In the cases of LVH with hypertension group, the serum cardiac parameter like NTpro-BNP was significantly raised. However, the serum myoglobin and CK-MB did not showed any significant rise when compared with control. In the cases of LVH without hypertension, all these three parameters not have shown any significant raise when compared with control.Conclusion: Apart from imaging techniques the assessment of serum NT- pro BNP act as better marker for identifying LVH than the traditional markers like CK-MB, myoglobin.
No takes yet. Share an insight, caveat, or question.
Raju et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: